LI-MIN HUANGLUAN-YIN CHANGTang H.Bock H.L.CHUN-YI LUHuang F.-Y.Lin T.-Y.Lee C.-Y.2020-12-152020-12-1520051054-139Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-27944432479&doi=10.1016%2fj.jadohealth.2005.08.009&partnerID=40&md5=ed5190ed49567d39eab2ebf10547af6dhttps://scholars.lib.ntu.edu.tw/handle/123456789/525670Purpose: Disease caused by Bordetella pertussis is increasingly being identified among older children and adults in immunized populations, indicating a waning of the vaccine-induced immunity. These findings suggest the need for booster immunization of older children and adults. Modern acellular reduced-antigen-content vaccines have been developed, which can be given as a booster in individuals more than 4 years of age. This study was to assess the immunogenicity and reactogenicity of Boostrix?, GlaxoSmithKline Biologicals' reduced-antigen-content diphtheria-tetanus acellular pertussis (dTpa) vaccine, when administered as a booster in healthy subjects previously primed with DTP vaccine. Methods: Healthy Taiwanese children and adolescents aged 6-8 years and 15-20 years, previously primed with DTP vaccine, were enrolled. All received one dose of Boostrix?. Two blood samples were taken from each of them, one before vaccination and one at 1 month after vaccination. Serum antibodies to diphtheria and tetanus toxoids and immunoglobulin G (IgG) antibodies against the pertussis components PT, FHA and PRN were measured by enzyme-linked immunosorbent assay (ELISA) technique. Adverse reactions following vaccination were recorded. Results: A total of 180 subjects were recruited. The vaccine response rates to the pertussis antigens ranged between 89.0-100%. There were no serious adverse events reported during the study period. Conclusions: The results of this study suggest that Boostrix? may be safely and effectively administered as a booster dose to children previously primed with DTP vaccine. ? 2005 Society for Adolescent Medicine. All rights reserved.[SDGs]SDG3antigen; diphtheria pertussis tetanus vaccine; filamentous hemagglutinin; hemagglutinin; immunoglobulin G antibody; pertactin; pertussis toxin; tetanus toxoid; unclassified drug; adolescent; adult; antibody blood level; article; blood sampling; child; clinical trial; diphtheria; drug induced disease; drug response; edema; enzyme linked immunosorbent assay; fatigue; female; fever; gastrointestinal symptom; headache; human; human tissue; immunogenicity; male; normal human; pain; pertussis; priority journal; protein content; tetanus; vaccinationjournal article10.1016/j.jadohealth.2005.08.009163101322-s2.0-27944432479